Year 2019 / Volume 111 / Number 8
Submission and tracking of manuscripts
Instructions to authors

Submission and tracking

REED Journal

REED Journal

Play video

Year 2019 / Volume 111 / Number 8


Survival, morbidity and mortality of pancreatic adenocarcinoma after pancreaticoduodenectomy with a total mesopancreas excision


Pablo Sánchez Acedo, Javier Herrera Cabezón, Cruz Zazpe Ripa, Antonio Tarifa Castilla,

Introduction: pancreatic adenocarcinoma is the most common malignancy in the periampullary region, with a five-year survival rate around 20%. Objective: the goal of our study was to determine the survival and safety data of a number of patients that underwent a cephalic duodenopancreatectomy (CDP) with total mesopancreas excision (TMPE). Material and methods: a prospective observational study was performed of 114 patients with pancreatic adenocarcinoma who underwent duodenopancreatectomy and TMPE over the period 2008-2017. Demographic variables, tumor stage, number of lymph nodes excised, lymph node ratio, R classification, the prognostic factor disease-free interval and survival were all assessed in a multivariate analysis. Results: complications were reported for 54 (47.3%) patients, of which 22 (19.3%) were categorized as serious. The mortality rate was 4.3% and the mean follow-up was 26.2 months. During this period, 73 (64%) patients relapsed after a mean interval of 40.9 months. The relapse pattern was mainly hepatic (26.3%), followed by local relapse (20%). Mean survival was 40.38 and actuarial survival was 26.6% at five years. Relapse-related factors included stage T3 or higher (RR 8.1 [1.1-61]) and an R1 resection (RR 13.4 [2.7-66.5]) and survival-related factors included an R1 resection (RR 10.7 [2.5-46.2]). Conclusion: TMPE ensures an adequate lymphadenectomy and lymph node ratio according to reported standards. The survival of patients that have undergone surgery for pancreatic adenocarcinoma in our institution is 68.4% at one year and 26.6% at five years. An R1 resection is the primary factor for both relapse and survival.

Valoración del lector: Valora este artículo:
Share Button
Send by e-mail

New comment

Security code:
CAPTCHA code image
Speak the codeChange the code


21/10/2019 6:36:57
Soy cirujano oncológo y me parece interesante ver las tasas de sobrevida en pacientes con cáncer de pancreas cuando se emplea la ETMP

Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
© 2020 The Spanish Journal of Gastroenterology